Loading news...
Omada Health, Inc. (OMDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program. By extending a previous six-month analysis , findings underscore the program's role in helping employers manage the complexity of today's weight loss medication market while delivering measurable, long-term value.1 The new analysis found that members who stayed in the program and persisted on their medication for 12 months had an average weight loss of 18.4% at one year,1 compared to 11.9% weight loss seen in real world evidence.2 Among those who persisted, Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide,1 compared to published real world evidence.2 Moreover, the analysis showed an increase in weight loss across all members in the program, including those who did and did not persist with GLP-1s for the entire year, with an average 16.3% weight loss1 – nearly twice the amount observed in the real world analysis.2 “The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits.
Cigna Investments Inc. New purchased a new position in Omada Health, Inc. (NASDAQ: OMDA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,444,630 shares of the company's stock, valued at approximately $76,161,000. Omada Health comprises about
Omada Health, Inc. (NASDAQ: OMDA - Get Free Report) President Wei-Li Shao sold 5,618 shares of the firm's stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the transaction, the president owned 69,079 shares in the company,
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk. Earnings and Valuation This table compares Establishment Labs
SAN FRANCISCO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, including a presentation on Wednesday, Jan. 14, at 9 a.m.
Federated Hermes Inc. bought a new stake in Omada Health, Inc. (NASDAQ: OMDA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 500,000 shares of the company's stock, valued at approximately $9,150,000. Federated Hermes Inc. owned 1.94% of Omada Health
Omada Health remains a 'Buy' as Q3 results validated strong growth, with revenue up 50% y/y to $68 million and membership reaching 831,000. OMDA's new GLP-1 prescribing capability deepens client integration, enhances ROI, and strengthens competitive positioning in a complex medication landscape. Multi-condition adoption accelerated, with ~75% of new customers using multiple programs, driving operating leverage and reducing client churn risk for OMDA.
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events . A replay will also be available at the same link following the event.
Pune, India, Nov. 18, 2025 (GLOBE NEWSWIRE) -- QKS Group announced that it has named Omada a Technology Leader and Emerging Innovator in the analysis of the global SPARK MatrixTM: Identity Governance and Administration (IGA), Q4 2025. The QKS Group SPARK Matrix™ includes a detailed analysis of the global market dynamics, major trends, vendor landscape, and competitive positioning. The study provides competitive analysis and ranking of the leading technology vendors in the form of its SPARK MatrixTM. The study offers strategic information for users to evaluate different provider capabilities, competitive differentiation, and market position.
Trump said Thursday that TrumpRx would offer discounts on GLP-1 drugs for weight loss. A few hours later, Omada Health said it will prescribe the drugs starting in 2026.
Omada Health, Inc. ( OMDA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Allan Kells - Vice President of Investor Relations Sean Duffy - Co-Founder, CEO & Director Wei-Li Shao - President Steven Cook - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Craig Hettenbach - Morgan Stanley, Research Division Richard Close - Canaccord Genuity Corp., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Saket Kalia - Barclays Bank PLC, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Gene Mannheimer Presentation Operator Good day, and thank you for standing by. Welcome to the Omada Health Third Quarter 2025 Earnings Conference Call.
The headline numbers for Omada Health, Inc. (OMDA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Revenue of $ 68 million, up 49% ; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights Total members of 831,000, up 53% compared with the third quarter of 2024 Revenue of $68 million, up 49% compared with the third quarter of 2024 Prescribing offering: announced plans to launch a new prescribing offering that will combine Omada's evidence-based behavior change program with medication management for anti-obesity medications (AOMs), including GLP-1s; the offering will tailor support before, during, and after treatment–designed to help improve member health outcomes and the value of AOM spend Clinical differentiation: published 30th peer-reviewed manuscript, which demonstrated significant cost savings from Omada's Joint & Muscle Health program, and released data showing that members in the analysis largely maintained their weight one year after discontinuing GLP-1 therapy — an outcome that challenges widespread assumptions of inevitable post-medication weight gain Omada Meal Map: launched Meal Map, an AI-powered nutrition experience that focuses on nutrient quality rather than calorie counting, building on OmadaSpark, the AI-driven nutrition education tool introduced earlier this year “Our third quarter results demonstrate the strength of Omada's multi-product platform in a moment of intense national focus on obesity-related chronic disease,” said Sean Duffy, Co-founder and CEO of Omada Health.
SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. After reporting 53% year-over-year member growth as of the end of Q3, the company is also expanding its offerings.
Virtual care company Omada Health said it will start prescribing GLP-1s and other obesity drugs and help patients manage those medications. The announcement expands the offerings under the company's weight management program as its membership grows to more than 100,000.
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not.
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology.
SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.